Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.
10.3350/cmh.2016.22.1.168
- Author:
Jong Wook CHOI
1
;
June Sung LEE
;
Woo Hyun PAIK
;
Tae Jun SONG
;
Jung Wook KIM
;
Won Ki BAE
;
Kyung Ah KIM
;
Jung Gon KIM
Author Information
1. Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. jsleemd@paik.ac.kr
- Publication Type:Case Reports
- Keywords:
Pegylated interferon alpha-2a;
Pancreatitis;
Hepatitis C virus
- MeSH:
Amylases/analysis;
Antiviral Agents/adverse effects/*therapeutic use;
Drug Therapy, Combination;
Female;
Hepatitis C, Chronic/diagnostic imaging/*drug therapy;
Humans;
Interferon-alpha/adverse effects/*therapeutic use;
Lipase/analysis;
Middle Aged;
Pancreatitis/*etiology;
Polyethylene Glycols/adverse effects/*therapeutic use;
Recombinant Proteins/adverse effects/therapeutic use;
Republic of Korea;
Ribavirin/therapeutic use;
Tomography, X-Ray Computed
- From:Clinical and Molecular Hepatology
2016;22(1):168-171
- CountryRepublic of Korea
- Language:English
-
Abstract:
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment for chronic HCV infection in Korea, which has considerable adverse effects. Acute pancreatitis is a rare complication of PEG-IFN-α administration. We report a case of a 62-year-old female who experienced acute pancreatitis after 4 weeks of PEG-IFN-α-2a and RBV combination therapy for chronic HCV infection. The main cause of the acute pancreatitis in this case was probably PEG-IFN-α rather than RBV for several reasons. A few cases have been reported in which acute pancreatitis occurred during treatment with PEG-IFN-α-2b. This is the first report of acute pancreatitis associated with PEG-IFN-α-2a in Korea.
